40% recovery: 4DMedical share price (ASX:4DX) turns sharply and delivers the goods

4DMedical caught bids this week and finished on top.

| More on:
rising medical asx share price represented by excited doctors dancing in ward

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Investors are bidding up the 4DMedical share price hard this week after a key announcement
  • The launch of the company's XV Scanner is a key driver to the commercialisation of its XV Technology strategy, it says
  • In the last 12 months, the 4DMedical share price has sunk by 44%

The 4DMedical Ltd (ASX: 4DX) share price climbed higher on Friday afternoon to close up 1.18% at 85.5 cents.

Investors appear to be rallying behind Thursday's announcement, which revealed the company is launching the world's first dedicated lung scanner.

The 4DMedical share price soared almost 20% yesterday. It's likely that momentum spilled over into today's session as trading volume surged well past its four-week average at 764,665 shares.

With big gains also on Tuesday and Wednesday, it means 4DMedical shares have surged 41% since last Friday's close. This week's gain is a welcome reprieve for 4D shareholders, who've seen their holdings evaporate over the past 12 months.

TradingView Chart

What's been happening at 4DMedical?

The company advised that it has installed the 'XV Scanner' at the Prince of Wales Hospital in Sydney after it was unveiled to the Federal health minister on Thursday.

4D says the scanner will provide unparalleled access to visually map the lung and provides "highly visual insight into lung function".

A successful launch will hopefully see the market adopt its XV Technology, something the company says is integral to successful commercialisation.

But the benefits extend primarily to the doctor-patient realm, and the scanner itself is considered somewhat a "breakthrough in innovation", according to Lung Foundation Australia CEO, Mark Brooke.

It's reported that seven million Australian currently are living with or are impacted by lung disease in some way, therefore any breakthrough would be a welcome sigh of relief to many.

Evans and Partners have 4DMedical rated as a speculative buy and value the company at $1.50 per share, suggesting an upside potential of 75% at the time of writing.

Meanwhile, Bell Potter has the company rated as a speculative hold but sets a price target of $2.07 per share — a mammoth 142% upside potential.

According to Bloomberg data, the consensus valuation is $1.78 per share, still a considerable amount of upside potential if the bull case plays out to that level.

4DMedical share price snapshot

In the last 12 months, the 4DMedical share price has sunk and is now 44% in the red. It is also down 36% this year to date.

Despite the 40% gain this week, shares have still fallen into the red by 5% over the past month.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A doctor looks unsure.
Healthcare Shares

Should you buy the rebound in CSL shares today?

Two leading experts deliver their verdicts for CSL shares.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Up 129% in a year, are Pro Medicus shares a buy ahead of tomorrow's FY 2025 results?

A leading expert delivers his verdict on the surging Pro Medicus share price.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Poor prognosis: Expert says sell these 2 ASX 200 healthcare giants now

Jed Richards from Shaw and Partners has a sell rating on both healthcare shares.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why this ASX 200 stock could jump 25%

Bell Potter has good things to say about this stock.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Guess which ASX All Ords stock just crashed 23% on earnings miss

Investors are sending the ASX All Ords stock tumbling on Friday. But why?

Read more »

Lab worker puts hands in the air and dances around.
Healthcare Shares

Guess which ASX 300 stock just jumped 12% on FDA approval

Investors are piling into the ASX 300 stock following big US news.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Healthcare Shares

Broker says Telix shares could surge 80% higher after selloff

Let's see what Bell Potter has to say about this beaten down healthcare share.

Read more »

A doctor looks unsure.
Dividend Investing

Down 11% in a year, are CSL shares now a good income buy?

CSL shares have faced headwinds from potential US pharmaceutical tariffs.

Read more »